{"analyses":[{"ciLowerLimit":"0.31","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.95","estimateComment":"Reference level = IMRT 5 weeks","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.93","pValueComment":"Two-side significance level = 0.05","paramType":"Hazard Ratio (HR)","paramValue":"0.95","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"98.1","upperLimit":"100","value":"99.3"},{"groupId":"OG001","lowerLimit":"95.7","upperLimit":"100","value":"98.0"}]}],"title":"Six months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"93.9","upperLimit":"99.5","value":"96.7"},{"groupId":"OG001","lowerLimit":"94.6","upperLimit":"99.9","value":"97.3"}]}],"title":"Two years"}],"denoms":[{"counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"149"}],"units":"Participants"}],"description":"Overall survival time is defined as time from randomization to the date of death or last known follow-up (censored). Overall survival rates are estimated by the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Cisplatin: 40 mg/m2 IV (intravenously) weekly for 6 weeks\n\nIMRT 6 weeks: Intensity-modulated radiation therapy (IMRT), 30 fractions over 6 weeks, 5 fractions per week, 2 Gray per fraction to total dose of 60 Gy","id":"OG000","title":"IMRT 6 Weeks + Cisplatin"},{"description":"IMRT 5 weeks: Intensity-modulated radiation therapy (IMRT), 30 fractions over 5 weeks, 6 fractions per week, 2 Gray per fraction to total dose of 60 Gy","id":"OG001","title":"IMRT 5 Weeks"}],"paramType":"NUMBER","populationDescription":"Randomized and eligible participants","reportingStatus":"POSTED","timeFrame":"from randomization to 2 years","title":"Percentage of Participants Alive","type":"SECONDARY","unitOfMeasure":"percentage of participants"}